RST-101
Post-Traumatic Stress Disorder (PTSD) - Early Treatment
PreclinicalActive
Key Facts
Indication
Post-Traumatic Stress Disorder (PTSD) - Early Treatment
Phase
Preclinical
Status
Active
Company
About ReST Therapeutics
ReST Therapeutics is a Paris-based biotech advancing novel small molecules targeting NMDA receptor subunits for neuropsychiatric conditions. The company's lead program, RST-101, targets early treatment of PTSD, while a second candidate, FENM, has entered clinical development. ReST leverages a precision neuropsychiatry platform, validated preclinical models, and a leadership team with deep drug development expertise, supported by high-profile scientific advisors like Professor John Krystal of Yale University.
View full company profile